Literature DB >> 12713078

Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.

Dimitrios Stamatiadis1, Maria G Papaioannou, Evangelos J Giamarellos-Bourboulis, Smaragda Marinaki, Helen Giamarellou, Charalambos P Stathakis.   

Abstract

OBJECTIVE: To achieve concentrations of teicoplanin in serum and dialysate within the therapeutic range in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
DESIGN: Pharmacokinetic study.
SETTING: A tertiary-care hospital. PATIENTS: Eight hospitalized anuric patients undergoing CAPD.
INTERVENTIONS: One single dose of 10 mg/kg teicoplanin was administered intravenously, and blood and dialysate were sampled at regular time intervals for 48 hours post drug infusion. Concentrations of teicoplanin were determined by microbiological assay.
RESULTS: Teicoplanin serum levels above 10 microg/mL, the level desired to treat systemic infections, were detected for 24 hours after administration. All dialysate concentrations were very low. Teicoplanin presented two phases of elimination: an early first phase and a late second phase. Mean maximum serum concentration was 75.56 microg/mL, mean half-life (t 1/2) of the early elimination was 3.34 hours, mean t 1/2 of the late elimination was 61.68 hours, mean area under the serum-concentration-time curve was 1491.92 mg x hr/L, mean clearance rate was 10.68 mL/ minute, mean apparent volume of distribution was 0.80 L/kg, and mean volume of distribution at steady state was 0.22 L/kg. Mean dialysate excretion was 3.16% and mean peritoneal clearance rate was 0.023 mL/minute.
CONCLUSIONS: Based on the time period with the achieved serum levels and on the prolonged t 1/2, it is proposed that teicoplanin might be administered at 10 mg/kg every 24 hours for the therapy of systemic infections in patients undergoing CAPD. However, its intravenous administration should be avoided in the treatment of peritonitis, because the achieved dialysate concentrations were very low.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713078

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  4 in total

1.  Intermittent intraperitoneal dose of teicoplanin in peritoneal dialysis-related peritonitis.

Authors:  V Liakopoulos; K Leivaditis; O Nikitidou; M Divani; G Antoniadi; N Dombros
Journal:  Perit Dial Int       Date:  2012 May-Jun       Impact factor: 1.756

Review 2.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.

Authors:  Marco Fiore; Alberto Enrico Maraolo; Ivan Gentile; Guglielmo Borgia; Sebastiano Leone; Pasquale Sansone; Maria Beatrice Passavanti; Caterina Aurilio; Maria Caterina Pace
Journal:  World J Gastroenterol       Date:  2017-07-07       Impact factor: 5.742

Review 4.  Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.

Authors:  Marco Fiore; Alberto Enrico Maraolo; Ivan Gentile; Guglielmo Borgia; Sebastiano Leone; Pasquale Sansone; Maria Beatrice Passavanti; Caterina Aurilio; Maria Caterina Pace
Journal:  World J Hepatol       Date:  2017-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.